Psychiatric News (4/30) reports, “While clozapine increases an individual’s risk of agranulocytosis (a drop in a type of white blood cell that can be life threatening) more than other antipsychotics, the risk of a serious adverse event is minimal and drops steeply after the first year of use, according to” researchers who “tracked nearly 62,000 people in Finland for up to 22 years” and “also found that the fatality rate among individuals who develop agranulocytosis is very low.” The results were published in The Lancet Psychiatry.
Related Links:
— “Risks of Clozapine Decline Sharply After Six Months, May Warrant Reduced Monitoring, Psychiatric News, April 30, 2024